s20098 has been researched along with Kidney Diseases in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 2 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Abd El-Ghafar, OAM; Alzoghaibi, MA; Hassanein, EHM; Mahmoud, AM | 1 |
| Cherngwelling, R; Lungkaphin, A; Pengrattanachot, N; Phengpol, N; Promsan, S; Sutthasupha, P; Swe, MT; Thongnak, L | 1 |
2 other study(ies) available for s20098 and Kidney Diseases
| Article | Year |
|---|---|
Agomelatine prevents gentamicin nephrotoxicity by attenuating oxidative stress and TLR-4 signaling, and upregulating PPARĪ³ and SIRT1.
Topics: Acetamides; Animals; Anti-Bacterial Agents; Anti-Inflammatory Agents; Gentamicins; Kidney Diseases; Male; Oxidative Stress; PPAR gamma; Protective Agents; Rats; Signal Transduction; Sirtuin 1; Toll-Like Receptor 4 | 2021 |
Agomelatine protects against obesity-induced renal injury by inhibiting endoplasmic reticulum stress/apoptosis pathway in rats.
Topics: Acetamides; Animals; Apoptosis; Diet, High-Fat; Endoplasmic Reticulum Stress; Gene Expression Regulation; Insulin Resistance; Kidney Diseases; Male; Obesity; Random Allocation; Rats; Rats, Wistar | 2021 |